Biotheryx

Biotheryx, based in San Diego, CA, is a biopharmaceutical company dedicated to advancing a portfolio of first-in-class protein degraders, primarily targeting cancer and inflammatory diseases. Utilizing their proprietary PRODEGY platform, the company is at the forefront of developing innovative drug discovery solutions that uniquely modulate the Cereblon protein for targeted protein degradation.

With a robust pipeline focused on oncology and inflammatory disorders, Biotheryx is committed to transforming patient treatment through its molecular glues and bifunctional degraders. The company has made significant strides in clinical trials, including the recent dosing of patients with its lead candidate, BTX9341, showcasing its potential to address historically challenging therapeutic targets.

Generated from the website